Working… Menu

Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease (PAPAYA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01410890
Recruitment Status : Recruiting
First Posted : August 5, 2011
Last Update Posted : October 3, 2019
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )

Brief Summary:
  • The primary objective of this study is to characterize the pharmacokinetics of alglucosidase alfa manufactured at the 4000 L scale in patients who have a confirmed diagnosis of Pompe disease.
  • A secondary objective of this study is to evaluate and explore the relationship between anti-rhGAA antibody titers and the pharmacokinetics of alglucosidase alfa.

Condition or disease Intervention/treatment Phase
Pompe Disease (Late-Onset) Glycogen Storage Disease Type II (GSD II) Biological: alglucosidase alfa Phase 4

Detailed Description:
The total study duration per patient will be 4 to 9 weeks that consist of a screening period (from 2 days to 4 weeks), treatment visit (1 day), and a follow up call (≥30 days).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease
Actual Study Start Date : November 3, 2014
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2020

Arm Intervention/treatment
Experimental: alglucosidase alfa
alglucosidase alfa intravenous (IV) infusion of 20mg/kg body weight
Biological: alglucosidase alfa
Intravenous (IV) infusion of 20mg/kg body weight every other week (qow)
Other Name: Lumizyme

Primary Outcome Measures :
  1. Maximum observed concentration (Cmax) [ Time Frame: Day 1 ]
  2. Actual sampling time to reach maximum observed concentration (Tmax) [ Time Frame: Day 1 ]
  3. Area under the concentration-time curve from 0 to the time of the last quantifiable concentration (AUC last) [ Time Frame: Day 1 ]
  4. Area under the concentration-time curve from time 0 and extrapolated to infinite time (AUC inf) [ Time Frame: Day 1 ]
  5. Terminal elimination half-life (T1/2) [ Time Frame: Day 1 ]
  6. Total systemic clearance (CL) [ Time Frame: Day 1 ]
  7. Volume of distribution (Vd) [ Time Frame: Day 1 ]

Secondary Outcome Measures :
  1. Pharmacokinetic (PK) parameters assessed in relation to anti-rhGAA antibody titers [ Time Frame: Day 1 ]
  2. Pharmacokinetic (PK) parameters assessed in relation to inhibitory/neutralizing anti-rhGAA antibody titers [ Time Frame: Day 1 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

A patient must meet all of the following criteria to be eligible for this study:

  • The patient and/or the patient's parent/legal guardian is willing and able to provide signed informed consent.
  • The patient has a confirmed GAA enzyme deficiency from skin, blood, or muscle tissue and/or 2 confirmed GAA gene mutations.
  • Infant and toddler Pompe disease patients can be included in the study only under condition (minimal body weight) that the trial-related blood loss (including any losses in the maneuver) will not exceed 3 percent of the total blood volume during a period of 4 weeks and will not exceed 1 percent at any single time.
  • The patient, if female and of childbearing potential, must have a negative pregnancy test (urine beta-human chorionic gonadotropin) at screening. Note: All female patients of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study.
  • For patients previously treated with alglucosidase alfa the patient has received alglucosidase alfa for at least 6 months.

Exclusion Criteria:

A patient who meets any of the following criteria will be excluded from this study:

  • The patient is participating in another clinical study using an investigational product.
  • The patient, in the opinion of the Investigator, is unable to adhere to the requirements of the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01410890

Layout table for location contacts
Contact: For site information, send an email with site number to
Contact: Medical Information 617-252-7832

Layout table for location information
United States, Ohio
Investigational Site Number 840007 Recruiting
Cincinnati, Ohio, United States, 45219
United States, Utah
Investigational Site Number 840005 Recruiting
Salt Lake City, Utah, United States, 84108
United States, Virginia
Investigational Site Number 840003 Recruiting
Fairfax, Virginia, United States, 22030
Investigational Site Number 1028 Recruiting
Sofia, Bulgaria, 1113
Investigational Site Number 356001 Completed
New Delhi, India, 110 029
Investigational Site Number 356002 Completed
Vellore, India, 632004
Russian Federation
Investigational Site Number 643001 Completed
Moscow, Russian Federation, 125367
Investigational Site Number 643002 Completed
Moscow, Russian Federation, 125412
Investigational Site Number 804001 Recruiting
Kiev, Ukraine, 01135
United Kingdom
Investigational Site Number 826003 Recruiting
Birmingham, United Kingdom, B4 6NH
Investigational Site Number 826002 Completed
Salford, United Kingdom, M6 8HD
Sponsors and Collaborators
Genzyme, a Sanofi Company
Layout table for investigator information
Study Director: Medical Monitor Genzyme, a Sanofi Company

Layout table for additonal information
Responsible Party: Genzyme, a Sanofi Company Identifier: NCT01410890     History of Changes
Other Study ID Numbers: AGLU07710
2010-022231-11 ( EudraCT Number )
MSC12790 ( Other Identifier: Sanofi )
First Posted: August 5, 2011    Key Record Dates
Last Update Posted: October 3, 2019
Last Verified: October 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Glycogen Storage Disease Type II
Glycogen Storage Disease
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Lysosomal Storage Diseases
Metabolic Diseases
Metabolism, Inborn Errors
Carbohydrate Metabolism, Inborn Errors